Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Outlook Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Outlook Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $17.36M, down 48.5% year over year. For fiscal 2025 it was $27.18M, down 34.9% from the year before. Over ten years it grew -3.5% a year on average. The highest annual figure on record is $42.33M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $27.18M | -34.9% |
| FY2024 | Sep 30, 2024 | $41.76M | +57.9% |
| FY2023 | Sep 30, 2023 | $26.45M | -37.5% |
| FY2022 | Sep 30, 2022 | $42.33M | +8.7% |
| FY2021 | Sep 30, 2021 | $38.96M | +47.9% |
| FY2020 | Sep 30, 2020 | $26.34M | +10.7% |
| FY2019 | Sep 30, 2019 | $23.81M | +28.6% |
| FY2018 | Sep 30, 2018 | $18.50M | -22.3% |
| FY2017 | Sep 30, 2017 | $23.81M | -27.3% |
| FY2016 | Sep 30, 2016 | $32.76M | -15.7% |
| FY2015 | Sep 30, 2015 | $38.88M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $3.25M | -54.4% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $4.50M | +2.1% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $3.63M | -62.4% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $5.98M | -52.3% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $7.13M | -36.3% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $4.41M | -67.4% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $9.66M | +113.3% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $12.52M | +153.3% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $11.20M | +0.9% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $13.51M | +2378.9% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $4.53M | -54.1% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $4.94M | -45.0% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $11.10M | +12.4% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $544.95K | -94.5% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $9.86M | -17.5% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $8.99M | +17.9% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $9.87M | +16.3% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $9.93M | +126.7% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $11.95M | +104.3% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $7.62M | +2.3% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $8.49M | +95.5% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $4.38M | -26.2% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $5.85M | -3.7% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $7.46M | +4.3% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $4.34M | -25.1% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $5.94M | +15.1% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $6.07M | +1408.8% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $7.15M | +210.2% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $5.80M | +39.4% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $5.16M | +25.3% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $402.40K | -97.0% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $2.30M | -40.5% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $4.16M | -65.4% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $4.12M | -0.5% |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $13.23M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $3.87M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $12.02M | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | $4.14M | – |
See a number that looks wrong?